• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    2/14/24 12:31:14 PM ET
    $AZTR
    $BTAI
    $COGT
    $ELMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZTR alert in real time by email

    Gainers

    • Cogent Biosciences (NASDAQ:COGT) stock increased by 64.0% to $8.96 during Wednesday's regular session. The company's market cap stands at $771.2 million.
    • Larimar Therapeutics (NASDAQ:LRMR) shares increased by 45.53% to $12.72. The company's market cap stands at $558.4 million.
    • BioXcel Therapeutics (NASDAQ:BTAI) stock rose 35.2% to $3.33. The company's market cap stands at $101.0 million.
    • Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 31.26% to $10.91. The company's market cap stands at $140.1 million.
    • Electromed (AMEX:ELMD) stock rose 22.61% to $12.43. The market value of their outstanding shares is at $106.6 million. As per the news, the Q2 earnings report came out yesterday.
    • Puma Biotechnology (NASDAQ:PBYI) shares moved upwards by 18.76% to $7.38. The market value of their outstanding shares is at $350.8 million.

    Losers

    • Anitra (AMEX:AZTR) stock declined by 71.3% to $0.25 during Wednesday's regular session. The market value of their outstanding shares is at $3.0 million.
    • QuidelOrtho (NASDAQ:QDEL) stock fell 29.1% to $47.34. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out yesterday.
    • NeuroOne Medical Tech (NASDAQ:NMTC) shares decreased by 16.35% to $1.18. The company's market cap stands at $30.5 million. As per the press release, Q1 earnings came out yesterday.
    • Renalytix (NASDAQ:RNLX) shares fell 14.9% to $1.2. The company's market cap stands at $59.9 million.
    • Sientra (NASDAQ:SIEN) shares declined by 14.22% to $0.17. The company's market cap stands at $2.0 million.
    • Sunshine Biopharma (NASDAQ:SBFM) shares declined by 12.51% to $0.06. The company's market cap stands at $1.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AZTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTR
    $BTAI
    $COGT
    $ELMD

    CompanyDatePrice TargetRatingAnalyst
    BioXcel Therapeutics Inc.
    $BTAI
    3/17/2026$17.00Buy
    Rodman & Renshaw
    Cogent Biosciences Inc.
    $COGT
    3/16/2026Buy
    Jefferies
    Cogent Biosciences Inc.
    $COGT
    11/10/2025$40.00Hold → Buy
    Stifel
    Cogent Biosciences Inc.
    $COGT
    11/10/2025$38.00Neutral → Outperform
    Wedbush
    Cogent Biosciences Inc.
    $COGT
    10/16/2025$16.00Hold
    Stifel
    QuidelOrtho Corporation
    $QDEL
    10/7/2025$33.00Buy → Neutral
    Citigroup
    Cogent Biosciences Inc.
    $COGT
    9/3/2025$30.00Strong Buy
    Raymond James
    Electromed Inc.
    $ELMD
    8/27/2025$36.00Buy
    Lake Street
    More analyst ratings

    $AZTR
    $BTAI
    $COGT
    $ELMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Wambeke David J. bought $670,400 worth of shares (1,000,000 units at $0.67) (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/3/26 8:49:19 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    * Director by Deputization Flynn James E bought $25,000,000 worth of shares (5,000,000 units at $5.00) (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 7:46:04 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hamilton Thomas Edward bought $500,000 worth of shares (100,000 units at $5.00), increasing direct ownership by 18% to 664,798 units (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 4:30:41 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    $BTAI
    $COGT
    $ELMD
    SEC Filings

    View All

    SEC Form S-8 filed by BioXcel Therapeutics Inc.

    S-8 - BioXcel Therapeutics, Inc. (0001720893) (Filer)

    3/27/26 5:10:10 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by BioXcel Therapeutics Inc.

    10-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)

    3/27/26 5:02:05 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Puma Biotechnology Inc

    SCHEDULE 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

    3/27/26 11:37:38 AM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    $BTAI
    $COGT
    $ELMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on BioXcel Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $17.00

    3/17/26 8:16:49 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Cogent Biosciences

    Jefferies resumed coverage of Cogent Biosciences with a rating of Buy

    3/16/26 9:35:47 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences upgraded by Stifel with a new price target

    Stifel upgraded Cogent Biosciences from Hold to Buy and set a new price target of $40.00

    11/10/25 11:01:45 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    $BTAI
    $COGT
    $ELMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting

    sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports potential approval as early as year-end 2026 Advancing commercial and launch plans based on third-party market assessment NEW HAVEN, Conn., March 27, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today reported financial results for the fourth quarter and full-year 2025 and provided an update on its late-stage pipeline and commercial launch readines

    3/27/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

    SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors.

    3/24/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

    Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA's review of available clinical data from open label studyContinued alignment with FDA to consider the use of skin FXN to support BLA submission seeking accelerated approval following recent START pilot program meetingTopline open label study data to support BLA submission expected in Q2 2026Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of first patient expected mid-2026Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved                                      

    3/19/26 7:00:00 AM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    $BTAI
    $COGT
    $ELMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    $BTAI
    $COGT
    $ELMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Hanson Bryan Michael

    3 - QuidelOrtho Corp (0001906324) (Issuer)

    3/24/26 4:40:52 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Salva Francisco D.

    4 - Azitra, Inc. (0001701478) (Issuer)

    3/20/26 4:30:30 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Mehta Vimal converted options into 383 shares, increasing direct ownership by 2% to 21,259 units (SEC Form 4)

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    3/16/26 8:05:59 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    $BTAI
    $COGT
    $ELMD
    Leadership Updates

    Live Leadership Updates

    View All

    Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

    SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors.

    3/24/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

    SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government affairs and portfolio management functions. Mr. Wolff brings over two decades of leadership experience in strategy, M&A and business development across the heal

    8/19/25 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AZTR
    $BTAI
    $COGT
    $ELMD
    Financials

    Live finance-specific insights

    View All

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 million in 2024. Based on accounting principles generally accepted in the United State

    2/26/26 4:05:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutic

    2/23/26 4:15:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    $BTAI
    $COGT
    $ELMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/26/24 8:42:10 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care